AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.

Several recent policy proposals are placing new pressures on the 340B drug pricing program, a decades-old federal initiative many hospitals and health systems depend on to offset the costs of care for ...

The 340B program, enacted by Congress in 1992, requires pharmaceutical companies to sell medications to rural hospitals at ...

The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s estimates, and HRSA should delay the program’s ...

The American Hospital Association wants the Health Resources and Services Administration to levy monetary penalties against Johnson & Johnson if the drug company continues with its plan to give 340B ...

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

In victory for struggling medical providers, law protecting a federal drug discount program in RI goes into effect despite opposition from drugmakers ...

Johnson & Johnson is asking a federal judge to declare its 340B rebate plan legal and prevent HHS and the Health Resources and Services Administration from taking any enforcement action against its ...